Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 19.50
Day High 20.50
Open:19.64
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada and the United States.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports+

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

HLS Therapeutics to Become Distributor of the Saladax MyCare(TM) Psychiatry Line including the Insite Point-of-Care Device and Antipsychotic Reagents
- CNW Group - Mon Jun 1, 5:30AM CDT
CNW Group - CMTX
Mon Jun 1, 5:30AM CDT
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces that it has become the exclusive Canadian distributor for the MyCareTM Insite point-of-care device and its related line of diagnostic tests from Saladax Biomedical, Inc. ("Saladax") of Bethlehem, Pennsylvania.
HLS Therapeutics Supports Trial to Investigate the Effects of Vascepa� (Icosapent Ethyl) against COVID-19
- CNW Group - Thu May 21, 3:07PM CDT
CNW Group - CMTX
Thu May 21, 3:07PM CDT
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that in collaboration with Amarin Corporation (NASDAQ:AMRN) it is supporting a trial to investigate the effects of Vascepa® (icosapent ethyl, or "IPE") on inflammatory biomarkers in individuals with COVID-19. The trial sponsored by the Canadian Medical and Surgical Knowledge Translation Research Group, is being led by Dr. Subodh Verma MD, PhD, FRCSC, FAHA, a cardiac surgeon?scientist at St Michael's Hospital in Toronto, Professor at the University of Toronto and Canada Research Chair in Cardiovascular Surgery, and Dr. Deepak L. Bhatt MD MPH, Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital and Professor, Harvard Medical School.
HLS Therapeutics Announces Q1 2020 Financial Results
- CNW Group - Thu May 7, 5:30AM CDT
CNW Group - CMTX
Thu May 7, 5:30AM CDT
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces its financial results for the three-month period ended March 31, 2020 ("Q1 2020"). All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 17.15 +15.63% increase
on 05/12/20
Period Open:18.57
Price movement based on the high, low and last over the given period.
21.48 -7.68% decrease
on 05/29/20
+1.26 (+6.79%) increase
since 05/05/20
3-Month 14.76 +34.35% increase
on 03/31/20
Period Open:21.42
Price movement based on the high, low and last over the given period.
21.60 -8.19% decrease
on 03/06/20
-1.59 (-7.42%) decrease
since 03/05/20
52-Week 12.91 +53.60% increase
on 09/04/19
Period Open:15.73
Price movement based on the high, low and last over the given period.
25.92 -23.50% decrease
on 12/31/19
+4.10 (+26.06%) increase
since 06/05/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies